专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2007131584A New benzoxazole derivative 审中-公开
标题翻译：新苯并噻唑衍生物
公开(公告)号：JP2007131584A
公开(公告)日：2007-05-31
申请号：JP2005327015
申请日：2005-11-11
申请人： Sankyo Co Ltd , 三共株式会社
发明人： UTO YOSHIICHI , KURATA HITOSHI , TANIMOTO TATSUO , KARASAWA HIROSHI , FURUHAMA TAKAFUMI
IPC分类号： C07D263/58 , A61K31/496 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P15/00 , A61P19/00 , A61P19/06 , A61P27/02 , A61P27/12 , A61P43/00 , C07D277/82 , C07D413/12 , C07D417/12
摘要： PROBLEM TO BE SOLVED: To provide a benzoxazole derivative having superior DGAT (diacylglycerol acyltransferase) inhibiting action or its pharmacologically permissible salt. SOLUTION: The benzoxazole derivative having a chemical structure expressed by general formula (I) (in which R 1 shows a hydrogen atom or the like; R 2 shows a 6-10C aryl group for which one to five pieces of groups selected from a substituent group 'a' may be independently substituted, or the like; E shows a group having a chemical structure expressed by formula (II) or formula (III), or the like; Q has an oxygen atom or a sulfur atom; or its pharmacologically permissible salt) are provided. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：要解决的问题：提供具有优异的DGAT（二酰基甘油酰基转移酶）抑制作用的苯并恶唑衍生物或其药理学上允许的盐。解决方案：具有由通式（I）表示的化学结构的苯并恶唑衍生物（其中R 1 表示氢原子等; R 2 表示选自取代基“a”中的1至5个基团的6-10C芳基可以独立地取代; E表示具有由式（II）或式（III）表示的化学结构的基团，或类似物; Q具有氧原子或硫原子;或其药理学上允许的盐）。版权所有（C）2007，JPO＆INPIT

2. 发明专利

JP2006045209A Urea derivative 审中-公开
标题翻译：尿素衍生物
公开(公告)号：JP2006045209A
公开(公告)日：2006-02-16
申请号：JP2005193260
申请日：2005-07-01
申请人： Sankyo Co Ltd , 三共株式会社
发明人： KURATA HITOSHI , UTO YOSHIICHI , FUJIBAYASHI YUKO , FURUHAMA TAKAFUMI , TANIMOTO TATSUO , KARASAWA HIROSHI
IPC分类号： C07D211/26 , A61K31/395 , A61K31/426 , A61K31/4418 , A61K31/451 , A61K31/4545 , A61K31/472 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/551 , A61K31/662 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P11/00 , A61P15/00 , A61P19/02 , A61P19/06 , A61P27/12 , A61P43/00 , C07D211/62 , C07D211/70 , C07D213/75 , C07D213/80 , C07D217/06 , C07D239/42 , C07D241/24 , C07D243/08 , C07D277/20 , C07D277/48 , C07D295/12 , C07D295/20 , C07D307/79 , C07D317/28 , C07D319/18 , C07D401/04 , C07D401/12 , C07D405/12 , C07D417/14
摘要： PROBLEM TO BE SOLVED: To obtain a urea derivative having excellent DGAT (diacylglycerol acyltransferase) inhibitory activity or its pharmaceutically permissible salt. SOLUTION: The urea derivative is represented by general formula (I) [R 1 is a 6-10C aryl group which may be independently substituted with 1-5 groups selected from a group (a) of substituent groups or the like; R 2 is a 6-10C aryl group which may be independently substituted with 1-5 groups selected from a group (a) of substituent groups or the like; E is a group containing a formula (II) or formula (II) (R 3 is a hydrogen atom or the like; R 4 and R 5 are each the same or different and a hydrogen atom or the like; X and U are each the same or different and a group represented by formula CH or the like; m and n the same or different and 1 or the like;); A is a group represented by formula NH-C(=O) or the like] or its pharmaceutically permissible salt. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：获得具有优异的DGAT（二酰基甘油酰基转移酶）抑制活性的尿素衍生物或其药学上可允许的盐。解决方案：脲衍生物由通式（I）表示[R SP 1]是可以独立地被1-5个选自（a）基团取代的6-10C芳基，的取代基等; R 2是可以独立地被选自取代基组（a）中的1-5个基团取代的6-10C芳基; E是含有式（II）或式（II）的基团（R 3 SP 3是氢原子等; R 4和R 5彼此， SP＆gt;各自相同或不同，为氢原子等; X和U各自相同或不同，由式CH等表示的基团，m和n相同或不同，1等） ; A是由式NH-C（= O）等表示的基团]或其药学上可允许的盐。版权所有（C）2006，JPO＆NCIPI

3. 发明专利

JP2009019013A New heteroarylpiperidine derivative 审中-公开
标题翻译：新型异丙肾上腺素衍生物
公开(公告)号：JP2009019013A
公开(公告)日：2009-01-29
申请号：JP2007183312
申请日：2007-07-12
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： UTO YOSHIICHI , KIYOZUKA YOHEI , KURATA HITOSHI , OGATA TSUNEAKI , OKUYAMA AKIRA , KONISHI MASAHIRO , KURIKAWA SHINYA , OSUMI JUN
IPC分类号： C07D401/04 , A61K31/501 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P15/08 , A61P27/12 , A61P43/00 , C07D401/14 , C07D409/14 , C07D413/14
摘要： PROBLEM TO BE SOLVED: To provide a heteroarylpiperidine derivative having excellent stearoyl-CoA desaturase inhibition or its pharmacologically acceptable salt. SOLUTION: The heteroarylpiperidine derivative is represented by formula (I) (wherein A is a group represented by the formula: -CONHR 1 or a group represented by the formula -ER 2 ; R 3 is hydrogen or the like; R 4 is hydrogen or the like; R 5 is a 6-10C aryl group which may be independently substituted with 1 to 5 substituents or the like; R 6 is hydrogen or a halogen; V is nitrogen or the like; W is nitrogen or the like; Y is a carbonyl group or the like; m is 0, 1 or 2; and n is 0, 1 or 2) and includes its pharmacologically acceptable salt. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供具有优异的硬脂酰-CoA去饱和酶抑制的杂芳基哌啶衍生物或其药理学上可接受的盐。解决方案：杂芳基哌啶衍生物由式（I）表示（其中A是由下式表示的基团-CONHR 1或由式-ER 2表示的基团< / SP>; R 3为氢等; R 4为氢等; R 6为6-10C芳基其可以独立地被1至5个取代基等取代; R 6是氢或卤素; V是氮等; W是氮等; Y是羰基或类似; m为0,1或2; n为0,1或2），并且包括其药理学上可接受的盐。版权所有（C）2009，JPO＆INPIT

4. 发明专利

JP2007191471A Medicine containing urea derivative 审中-公开
标题翻译：含尿素衍生物的药物
公开(公告)号：JP2007191471A
公开(公告)日：2007-08-02
申请号：JP2006340724
申请日：2006-12-19
申请人： Sankyo Co Ltd , 三共株式会社
发明人： KURATA HITOSHI , UTO YOSHIICHI , FUJIBAYASHI YUKO , FURUHAMA TAKAFUMI , TANIMOTO TATSUO , KARASAWA HIROSHI
IPC分类号： A61K31/4409 , A61K31/4545 , A61K31/472 , A61K31/495 , A61K31/496 , A61K31/551 , A61K31/675 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P15/00 , A61P19/02 , A61P19/06 , A61P27/12 , A61P43/00 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/79 , C07D217/06 , C07D243/08 , C07D277/20 , C07D277/42 , C07D295/20 , C07D307/82 , C07D319/18 , C07D401/12 , C07D417/12 , C07F9/568
摘要： PROBLEM TO BE SOLVED: To provide a medicine containing an urea derivative having excellent DGAT (Acyl-CoA:diacylglycerol acyltransferase)-inhibiting action or its pharmacologically permissible salt as an active ingredient. SOLUTION: The medicine comprises an urea derivative represented by general formula (I) [wherein R 1 is a 6-10C aryl group or the like which independently be substituted with 1-5 groups selected from a substituent group (a); R 2 is a 6-10C aryl group or the like which independently be substituted with 1-5 groups selected from the substituent group (a); E is a group or the like having formula (II) or formula (III); A is a group or the like represented by the formula -NH-C(=O)-] or its pharmacologically permissible salt as an active ingredient. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供含有具有优异的DGAT（酰基-CoA：二酰基甘油酰基转移酶）抑制作用的尿素衍生物或其药理学上允许的盐作为活性成分的药物。解决方案：该药物包含由通式（I）表示的脲衍生物[其中R 1是一个6-10C芳基等，其独立地被1-5个选自以下的基团取代：取代基（a）; R 2是独立地被选自取代基（a）中的1-5个基团取代的6-10C芳基等; E是具有式（II）或式（III）的基团等; A是由式-NH-C（= O） - ]表示的基团或其药理学上允许的盐作为活性成分。版权所有（C）2007，JPO＆INPIT

5. 发明专利

JP2011088889A Medicine containing new tetrahydroisoquinoline derivative 审中-公开
标题翻译：含有新四氢喹啉衍生物的药物
公开(公告)号：JP2011088889A
公开(公告)日：2011-05-06
申请号：JP2010211511
申请日：2010-09-22
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： UTO YOSHIICHI , KARASAWA HIROSHI , TAKAISHI MASAZUMI
IPC分类号： C07D217/06 , A61K31/472 , A61K31/4725 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P27/12 , A61P43/00 , C07D401/12 , C07D405/12
摘要： PROBLEM TO BE SOLVED: To provide medicines containing as effective ingredients, the compounds having excellent effects of inhibiting DGAT and suppressing food intake, or pharmacologically acceptable salts thereof. SOLUTION: The invention relates to medicines containing the compounds represented by general formula (I) or pharmacologically acceptable salts thereof as effective ingredients (wherein R 1 is a phenylaminocarbonyl group, one to five of which may independently be replaced with the groups selected from a substituent group A, a benzoxazol-2-yl group, one to three of which may independently be replaced with the groups selected from the group A or the like; R 2 is independently a 1-6C alkyl group; R 3 is a group shown by formula: -C(=O)-O-R 4 or the like; R 4 is hydrogen, a 1-6C alkyl group, one to three of which may independently be replaced with the groups selected from a substituent group B or the like; X is oxygen, a methylene group, -NH- or the like; and L is a single bond, a methylene group or the like). COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：待解决的问题：为了提供含有作为有效成分的药物，具有优异的抑制DGAT并抑制食物摄入的效果的化合物或其药理学上可接受的盐。解决方案：本发明涉及含有由通式（I）表示的化合物或其药理学上可接受的盐作为有效成分的药物（其中R 1 是苯基氨基羰基，其中1至5个可以独立地被选自取代基组A，苯并恶唑-2-基的基团取代，其中1至3个可以独立地被选自A等的基团取代; R 2 SP >独立地是1-6C烷基; R 3是由下式表示的基团-C（= O）-OR 4，其中R 1，R 2， 4 是氢，1-6C烷基，其中1至3个可以独立地被选自取代基组B等的基团取代; X是氧，亚甲基，-NH-或并且L是单键，亚甲基等）。版权所有（C）2011，JPO＆INPIT

6. 发明专利

JP2007210929A Medicine containing urea compound 审中-公开
标题翻译：含有尿素的药物
公开(公告)号：JP2007210929A
公开(公告)日：2007-08-23
申请号：JP2006031789
申请日：2006-02-09
申请人： Sankyo Co Ltd , 三共株式会社
发明人： HAYAKAWA ICHIRO , YOSHIDA MASAO , SUGANO YUICHI , KURATA HITOSHI , FURUHAMA TAKAFUMI , TANIMOTO TATSUO , KARASAWA HIROSHI , UTO YOSHIICHI
IPC分类号： A61K31/417 , A61K31/4196 , A61K31/422 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/506 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/12 , A61P15/00 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P27/12 , A61P29/00 , A61P43/00 , C07D233/64 , C07D249/08 , C07D249/12 , C07D277/28 , C07D285/12 , C07D401/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/12
摘要： PROBLEM TO BE SOLVED: To provide a medicine having an excellent DGAT (diacyl glycerol acyl transferase) inhibitory activity. SOLUTION: This medicine is provided by containing a urea derivative expressed by general formula (I) [wherein, R 1 is a 6-10C aryl or the like; R 2 is a 6-10C ary or the like; R 3 , R 4 are each H or the like; A is a 2-4C alkylene or the like; Q is a group expressed by formula: -N(Me)- or S; T is a group expressed by formula: =CH- or N; U, V are each the same or different and are each a group expressed by formula: =CH- or the like] or it pharmacologically acceptable salt as an active ingredient. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供具有优异DGAT（二酰基甘油酰基转移酶）抑制活性的药物。解决方案：该药物通过含有通式（I）表示的脲衍生物[其中，R 6 = 6-10C芳基等; R 2 是6-10C等等; R 3 ，R 4 分别为H等; A是2-4C亚烷基等; Q是由下式表示的基团：-N（Me） - 或S; T是由下式表示的基团：= CH-或N; U，V各自相同或不同，各自为由式= CH-等表示的基团）或其药理学上可接受的盐作为活性成分。版权所有（C）2007，JPO＆INPIT

7. 发明专利

JP2006083158A Substituted urea compound 审中-公开
标题翻译：替代尿素化合物
公开(公告)号：JP2006083158A
公开(公告)日：2006-03-30
申请号：JP2005231429
申请日：2005-08-10
申请人： Sankyo Co Ltd , 三共株式会社
发明人： HAYAKAWA ICHIRO , YOSHIDA MASAO , SUGANO YUICHI , KURATA HITOSHI , FURUHAMA TAKAFUMI , TANIMOTO TATSUO , KARASAWA HIROSHI , UTO YOSHIICHI
IPC分类号： C07D249/08 , A61K31/4196 , A61K31/4439 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/12 , A61P15/08 , A61P19/02 , A61P19/06 , A61P27/02 , A61P43/00 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/12 , C07D413/12
摘要： PROBLEM TO BE SOLVED: To provide a urea derivative having excellent DGAT (diacylglycerol acyltransferase) inhibitory action or its pharmacologically acceptable salts. SOLUTION: The urea derivative is represented by general formula (I) [wherein R 1 and R 2 are each a 6C-10C aryl group which may be substituted by a group selected from the substituting groups (a) and/or one to four groups which may independently selected from the substituting groups (b) or the like; R 3 and R 4 are identical or different each other and is H atom or the like; A is a 2C to 4C alkylene group of which a methylene group in the main chain may be substituted with a vinylene, an O atom, an S atom, a sulfinyl group or a sulfonyl group; Q is a group represented by formula -N(Me)- or S atom; T is a group represented by formula =CH- or N atom; U and V are identical or different and is represented by the formula =CH- or the like] or their pharmacologically acceptable salts. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供具有优异DGAT（二酰基甘油酰基转移酶）抑制作用的尿素衍生物或其药理学上可接受的盐。解决方案：脲衍生物由通式（I）表示[其中R 1 SP 1和R 2 SP 2各自为可被以下基团取代的6C-10C芳基：选自取代基（a）和/或一至四个可以独立地选自取代基（b）等的基团的基团; R 3 和R 4 彼此相同或不同，为H原子等; A是主链中的亚甲基可以被亚乙烯基，O原子，S原子，亚磺酰基或磺酰基取代的2至4个亚烷基; Q是由式-N（Me） - 或S原子表示的基团; T是由式= CH-或N原子表示的基团; U和V相同或不同，由式= CH-等表示）或其药理学上可接受的盐。版权所有（C）2006，JPO＆NCIPI

8. 发明专利

JP2010215640A Novel tetrahydroisoquinoline derivative 审中-公开
标题翻译：新四氢喹啉衍生物
公开(公告)号：JP2010215640A
公开(公告)日：2010-09-30
申请号：JP2010110895
申请日：2010-05-13
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： UTO YOSHIICHI , KARASAWA HIROSHI , TAKAISHI MASAZUMI
IPC分类号： C07D217/06 , A61K31/472 , A61K31/4725 , A61K31/497 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/12 , A61P15/00 , A61P19/00 , A61P19/06 , A61P25/02 , A61P27/02 , A61P43/00 , C07D401/12 , C07D413/12 , C07D417/12
CPC分类号： C07D217/06 , A61K31/47 , C07D401/12 , C07D413/12 , C07D417/12
摘要： PROBLEM TO BE SOLVED: To provide a compound having an excellent DGAT (acyl-coenzyme A) inhibiting activity and an excellent anorexigenic activity or a pharmacologically acceptable salt thereof. SOLUTION: There is provided the compound or the pharmacologically acceptable salt represented by general formula (I) [in the formula, R 1 represents a phenylaminocarbonyl group which may be substituted by 1 to 5 substituents independently selected from the members of the substituent group (A), a benzoxazol-2-yl group which may be substituted by 1 to 3 substituents independently selected from the members of the substituent group (A), or the like; R 2 is an alkyl group; R 3 represents a group represented by formula -C(=O)-O-R 4 , or the like; R 4 represents a hydrogen atom, an alkyl group which may be substituted by substituents independently selected from the members of the substituent group (B), or the like; X represents an oxygen atom or the like; L represents a methylene group, or the like; a dot-line represents a single bond or a double bond; m represents a number of 1 or 2; n represents an integer of 0 to 5; the substituent group (A) includes a halogen atom, and others; the substituent group (B) includes a phenyl group and others]. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供具有优异的DGAT（酰基辅酶A）抑制活性和优异的厌食性活性的化合物或其药理学上可接受的盐。提供由通式（I）表示的化合物或药理学上可接受的盐[在式中，R“SP”表示可以被1至5个取代基独立地取代的苯基氨基羰基选自取代基（A）的成员，可以被1至3个取代基取代的苯并恶唑-2-基，其独立地选自取代基（A）的成员等; R 2是烷基; R 3表示由式-C（= O）-O-R“SP 4”表示的基团等; R 4表示氢原子，可以被独立地选自取代基（B）的成员的取代基取代的烷基等; X表示氧原子等; L表示亚甲基等; 点划线表示单键或双键; m表示1或2的数字; n表示0〜5的整数，取代基（A）包括卤素原子等; 取代基（B）包括苯基等]。版权所有（C）2010，JPO＆INPIT

9. 发明专利

JP2010100548A Medicine containing new amide derivative 审中-公开
标题翻译：含有新型衍生物的药物
公开(公告)号：JP2010100548A
公开(公告)日：2010-05-06
申请号：JP2008271928
申请日：2008-10-22
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： UTO YOSHIICHI , KIYOZUKA YOHEI , KURATA HITOSHI , OGATA TSUNEAKI , OKUYAMA AKIRA , ABE MANABU , HARADA ATSUSHI , KONO KEITA
IPC分类号： A61K31/381 , A61K31/426 , A61K31/433 , A61P1/16 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P11/00 , A61P19/02 , A61P19/06 , A61P27/12 , A61P43/00 , C07D277/20 , C07D277/44 , C07D277/56 , C07D285/12 , C07D285/135 , C07D333/36 , C07D333/38
摘要： PROBLEM TO BE SOLVED: To provide a medicine containing a compound having excellent stearoyl CoA desaturase-inhibiting actions or a pharmacologically acceptable salt thereof. SOLUTION: The medicine contains the compound having general formula (I) [wherein, R 1 is a hydroxy group, a 1C-6C alkoxy group, a 2C-6C hydroxyalkoxy group or the like; R 2 is a hydroxy group, a 1C-6C alkoxy group, a 2C-6C hydroxyalkoxy group or the like; R 3 is a hydrogen atom or the like; R 4 is a 6C-10C aryl group which may be independently substituted with one to five groups selected from the group A of substituent groups, or the like; V is a group represented by the formula: -NH- or a single bond; W is a group represented by the formula: -NH- or a single bond; T is a group represented by the formula: =C(R 5 )- or a nitrogen atom; and Q is a group represented by the formula: =C(R 6 )- or a nitrogen atom] or a pharmacologically acceptable salt thereof. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供含有硬脂酰CoA去饱和酶抑制作用优异的化合物或其药理学上可接受的盐的药物。药物含有具有通式（I）的化合物[其中，R SP 1是羟基，1C-6C烷氧基，2C-6C羟基烷氧基等; R 2是羟基，1C-6C烷氧基，2C-6C羟基烷氧基等; R 3是氢原子等; R 6是可以独立地被一至五个选自取代基组A的基团取代的6C-10C芳基等; V是由下式表示的基团：-NH-或单键; W是由下式表示的基团：-NH-或单键; T是由下式表示的基团：= C（R 5 SP 5） - 或氮原子; Q为由式= C（R 6 SP 6）或氮原子表示的基团）或其药理学上可接受的盐。版权所有（C）2010，JPO＆INPIT

10. 发明专利

JP2009269850A Pharmaceutical containing new spiropiperidine derivative 审中-公开
标题翻译：含有新型螺吡啶衍生物的药物
公开(公告)号：JP2009269850A
公开(公告)日：2009-11-19
申请号：JP2008120937
申请日：2008-05-07
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： UTO YOSHIICHI , KIYOZUKA YOHEI
IPC分类号： A61K31/501 , A61K31/55 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P15/00 , A61P19/02 , A61P19/06 , A61P27/12 , C07D221/20 , C07D487/10 , C07D491/10 , C07D495/10
摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical containing a compound having an excellent action of inhibiting stearoyl-CoA desaturase or a pharmacologically acceptable salt thereof. SOLUTION: Provided is a pharmaceutical containing a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. COPYRIGHT: (C)2010,JPO&INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式